LEADS BIOLABS-B (09887) rose more than 4%, with the stock up 4.39% to HK$93.9 at the time of writing. The trading volume was HK$13.3778 million. On April 8, LEADS BIOLABS announced that the preliminary safety evaluation for the Phase II clinical study of its self-developed PD-L1/4-1BB bispecific antibody, LBL-024 (Vilisin®), as a first-line treatment for advanced biliary tract cancer has been completed. Based on favorable safety and encouraging efficacy data, the project has smoothly progressed into the expansion phase, with the first patient already enrolled. Data indicates that Vilisin® in combination with chemotherapy demonstrated a good overall safety profile and tolerability, with no new safety signals identified. Preliminary efficacy assessments revealed an encouraging trend of tumor shrinkage. Owing to the positive safety and efficacy results, the project has successfully entered the expansion stage and is accelerating its development.